International Cannabis Business Conference Blog – Page 93 – International Cannabis Business Conference

Will Barcelona’s Cannabis Industry Reach Its Full Potential?

Written by Hazel Norman on January 12, 2023. Posted in Business, Entertainment, Policy.

Barcelona, Spain is the social cannabis use capital of the world. Home to hundreds of cannabis lounges and clubs, Barcelona’s cannabis community and consumer experience is unique in every way. Unfortunately, the public policies in Spain pertaining to such establishments do not currently align with reality, with many lawmakers and regulators choosing to stick their heads in the sand and act as if Barcelona’s emerging industry doesn’t exist.

That approach by many lawmakers and regulators does a huge disservice to not only people involved in the cannabis trade, but also the rest of society which would benefit from a regulated industry. Just as the adult-use cannabis industry is generating a significant economic impact in Canada, so too could it do the same in Spain, particularly in Barcelona.

Generating Jobs and Tax Revenue

Every member of a society benefits from a boost in the economy to some degree, particularly when that boost comes from afar. When cannabis enthusiasts travel to an area to partake in cannabis commerce, they need rides to and from lounges, they eat and shop in the area, and they pay for lodging, among many other things. The larger the tourist population, the more local people benefit from the increased commerce.

In Barcelona, all the cannabis consumption at clubs and lounges occurs in private settings, so the mere activity of consuming cannabis is not a nuisance, and thus, the economic boost is clearly a net gain to the region. Cannabis tourism generates jobs, and if the industry is regulated, it also generates taxes and fees that go to public coffers, which is one of the many reasons why Spain should be embracing Barcelona’s clubs and lounges instead of making them operate in limbo. Additionally, society benefits from no longer having public revenue earmarked for enforcing failed public policy (cannabis prohibition).

How to Address the Issue?

Ultimately, it is up to lawmakers in Spain to pass comprehensive cannabis reform at the national level in order to get Barcelona’s emerging cannabis industry built on a solid legal foundation. Local leaders in Barcelona previously adopted a limited regulatory model for cannabis clubs just to see the policy later thrown out by the nation’s top Court, so there’s likely nothing meaningful that can be done at the local level.

Public pressure must reach a critical mass to hold lawmakers accountable when they drag their feet on cannabis reform, and if they will still refrain from taking meaningful action, they need to be replaced with people that will act. Any pressure campaign must involve a heavy dose of public education to combat any misinformation being spread by opponents, and to help convince people that are on the fence about the issue to get on the right side of history.

Leaders Coming Together

Barcelona’s rich cannabis history and culture makes it once again the perfect backdrop to the International Cannabis Business Conference trade show, taking place March 9, 2023. Cannabis policymakers and industry leaders from all over the globe will be in attendance, and one of the major focuses of the conference will be how to move Spain’s industry forward.

The International Cannabis Business Conference is the leading cannabis business to business (B2B) event series on the planet, with previous conferences occurring in several countries on multiple continents. The event series is owned and operated by cannabis advocates that believe in celebrating cannabis culture, in addition to providing world-class cannabis industry education and networking opportunities.

The International Cannabis Business Conference has once again partnered with Spannabis, Europe’s top cannabis expo, to form another super-event that is a must-attend for anyone that is serious about succeeding in the emerging cannabis industry. Spannabis originally teamed up with the International Cannabis Business Conference in 2019, and the collaboration was a tremendous success. The 2023 super-event will be bigger and better than ever, with the collaboration event being the largest of its kind. Participating speakers and an event schedule will be announced soon.

Could Malta Help Move the Needle?

One thing that will be interesting to observe is what is currently unfolding in Malta. Malta passed a national adult-use legalization measure late last year, making it the first country in Europe to do so.

The measure was largely built on the premise of consumers obtaining their cannabis from non-profit cannabis clubs. The only other way for adults to obtain cannabis is to cultivate it themselves or to be gifted it.

It is unclear right now how long it will be after applications are initially collected before the first regulated club is opened, however, things do seem to be moving along. Once Malta officially rolls out its cannabis club licenses and sets up all the processes and regulations pertaining to it, it will have created a blueprint for other countries to mimic, including and especially Spain.

New Medical Cannabis Industry Regulations Delayed In Spain

Written by Hazel Norman on January 9, 2023. Posted in Business, Policy.

Back in June 2022 Spain’s Health and Consumption Commission of the Congress of Deputies approved an opinion of the Medical Cannabis Subcommittee which called for medical cannabis industry regulations.

Part of that approved opinion involved tasking the Spanish Agency for Medicines and Health Products (Aims) to come up with a regulatory plan within 6 months regarding how it would implement the recommendations of the approved opinion.

That six-month deadline expired in December 2022, and here we are in 2023 and it’s still unclear when the plan will be released. Per El Espanol (translated to English):

The agency dependent on the Ministry of Health coordinated by Carolina Darias had a period of 6 months to prepare a document with recommendations so that the regulations have legal requirements and are “viable”. The problem? That document has not arrived. And we are already in 2023.

This means that Health has not met the deadlines and that the great project of Podemos -which the PSOE later embraced- to make medical marijuana a reality before the May elections is complicated.

The government in Spain failing to meet a mandated, cannabis-based deadline is not entirely unique. In October 2018 Mexico’s Supreme Court rendered a decision that deemed cannabis prohibition to be unconstitutional, and tasked lawmakers with passing a legalization measure within a year.

Clearly, lawmakers in Mexico did not meet that original deadline, and have also failed in meeting subsequent deadlines. What is going on in Spain is not an apples to apples comparison to what is going on in Mexico, however, it does highlight that when deadlines are not met it leaves cannabis advocates inside and outside of government scrambling to try to find ways to move the needle in the country where delays are occurring.

We will make sure to continue to keep a very close eye and to monitor the situation in Spain for signs of movement.

Cannabis Seizures At U.S./Mexico Border Fall To Historic Lows

Written by Frank Schuler on January 9, 2023. Posted in Policy.

By many measures the border shared by the United States and Mexico has served as ground-zero for the war on cannabis. It’s no secret that for many years cannabis, among other things, was smuggled from Mexico into the United States via various entry points along the nations’ shared border.

Starting in 1996 the demand for cannabis smuggled from Mexico into the United States started to be impacted by domestic cannabis reform in the U.S., with California becoming the first state to pass a medical cannabis legalization measure in U.S. history.

Between 1996 and 2012 several other states also passed medical cannabis legalization measures, many of which involved the launch of a regulated industry, and in 2012 two states passed the nation’s first set of adult-use legalization measures. Every state-level industry that launched in the U.S. further reduced the demand for smuggled cannabis from Mexico.

Cannabis is still smuggled into the U.S. from Mexico, however, the rate of it happening continues to dwindle, as reflected by recent seizure statistics from the United States Border Patrol. Below is more information about it via a NORML news release:

Washington, DC: Federal law enforcement agents are intercepting historically low quantities of cannabis at the southern border, according to newly released data provided by the US Department of Homeland Security, US Customs and Border Protection.

Federal statistics reveal that Border Patrol and Field agents confiscated an estimated 155,000 pounds of marijuana at the US/Mexico border in 2022. That is down almost 50 percent from 2021 totals and continues the dramatic decline in seizure volume that began in 2013, when nearly 3 million pounds of cannabis were confiscated at the southern border.

Some experts have previously speculated that licensed retail access to cannabis products, which began in Colorado and Washington in 2014 and is now available in almost half of all states, has significantly undercut demand for imported Mexican cannabis. According to conclusions provided by the US Drug Enforcement Administration, “In US markets, Mexican marijuana has largely been supplanted by domestic-produced marijuana.”

Separate data published last year by the Government Accounting Office and elsewhere indicates that interdiction efforts along the US border now typically involve the seizure of small quantities of marijuana and no other controlled substances.

Drug seizure statistics are available online from the US Customs and Border Protection website.

Will Costa Rica Become A Top Cannabis Tourism Destination?

Written by Hazel Norman on January 9, 2023. Posted in Business, Entertainment, Policy.

Cannabis tourism is not a new thing, however, the size of that particular sector of the emerging international cannabis industry has historically been limited. Obviously, that is due in large part to prohibition laws around the globe.

For many years Amsterdam was the undeniable leader when it came to international cannabis tourism, with a handful of other notable cities such as Barcelona and Vancouver (Canada) also serving as top destinations for cannabis enthusiasts.

As cannabis reform continues to spread across the globe, and with it, the legal cannabis industry, lawmakers in some countries are seeming to envision their regions also serving as top international cannabis tourism destinations, with the latest example of that being in Costa Rica. Per The Q Media (translated to English):

The bill to legalize the use of recreational marijuana in Costa Rica authorizes the Instituto Costarricense de Turismo (ICT) – Costa Rican Tourism Board – to promote the country as a destination for responsible consumption.

This is established in article 52 of initiative 23,383 that is being analyzed by the legislative commission on the environment (Comisión de Ambiente del Congreso).

Specifically, it indicates:

“The Instituto Costarricense de Turismo should establish information campaigns at the international level to promote Costa Rica as a tourist destination for the responsible consumption of cannabis for recreational use.”

The bill itself is far from guaranteed to pass, so the language pertaining to boosting cannabis tourism needs to be taken with a grain of salt. Cannabis advocates inside and outside of Costa Rica are clearly rooting for legalization to be adopted in Costa Rica, however, as with all things political, no one should count any eggs before they hatch.

According to World Data, “Costa Rica recorded a total of one million tourists in 2020, ranking 90th in the world in absolute terms.” With that in mind, any and all additional tourism that cannabis legalization can generate for Costa Rica will surely be appreciated.

Which Country Is More Likely To Legalize In 2023 – The U.S. Or Germany?

Written by Johnny Green on January 8, 2023. Posted in Policy.

When it comes to the ongoing fight to end global cannabis prohibition, there’s a saying that I often use – the bigger the nation’s economy, the bigger the domino. Don’t get me wrong, I certainly believe that cannabis legalization in every country is significant, and that any such victory should be thoroughly celebrated. However, there’s clearly a difference from an overall momentum-building standpoint between nations in regards to cannabis politics, and that is largely based on economic clout in the international community. For evidence of that, consider how much of the international cannabis community’s focus is dedicated to monitoring what is going on in Germany and the United States.

The United States and Germany are two of the top four economies on earth, ranked first and fourth respectively. The other two countries that round out the top four are China (second), and Japan (third), and as anyone that monitors international cannabis politics will be quick to point out, China and Japan are trending in the wrong direction and will not be legalizing cannabis for adult-use anytime soon. Conversely, both the United States and Germany are trending in the right direction, with advocates in both nations pushing harder than ever to end cannabis prohibition at the federal level within their borders. Advocates around the world are watching closely to see if either domino falls in 2023 because, after all, either domino falling would dramatically boost the chances of legalization efforts happening elsewhere on the planet.

Will The United States Legalize In 2023?

The United States is a very unique place when it comes to cannabis policy. At the federal level cannabis is a Schedule I substance and is greatly restricted, although hemp is legal and limited cannabis research is also permitted. Meanwhile, cannabis is legal for adult-use in a growing number of states and is legal in medical form to some degree in nearly every state. It makes for an interesting situation from a political science standpoint in that every year cannabis reform seems to spread at the local level in the United States while legalization at the federal level remains elusive.

A new Congress was recently sworn in after a federal election in the U.S., and it’s virtually guaranteed that no major legislation will be able to pass through both chambers in the next two years due to each chamber being controlled by opposing political parties. Cannabis reform, unfortunately, is going to presumably take a back seat to 24 months of partisan food fighting in the U.S. Arguably the saddest irony from a political science standpoint is that federal cannabis legalization is extremely popular in the United States, with Gallup’s most recent annual legalization poll holding steady at a 68% approval level for legalization. You will be hard-pressed to find anything in U.S. politics right now that has that level of support among all voters.

Cannabis advocates in the U.S. have remained hopeful year after year that federal legalization would finally happen in some fashion just to have their hopes dashed, and I personally think that the odds for legalization were better in the last Congress than this new one. Divisiveness is at the top of the menu in Washington D.C. right now, and even limited cannabis reform measures are likely to languish in the 118th Congress, with full legalization almost certainly being completely out of reach for the time being.

Will Germany Legalize In 2023?

Legalization’s progress in Germany may not currently be as some want it to be, myself included, however, Germany has a far greater chance of passing a federal adult-use legalization measure in 2023 compared to the United States. Pro-cannabis lawmakers in Germany have gone as far as blocking some of the Health Ministry’s funding due to delays in the introduction of an adult-use legalization measure. Politics and federal funding work different in the U.S. compared to Germany, and yet even with that factored in, there’s no equivalent level of pressure being incorporated by lawmakers in the United States right now. Performative federal cannabis legalization rhetoric is abundant in the U.S. Congress’ hallways, but actual action is rare on both sides of the aisle.

Germany’s Health Minister is currently trying to make his case at the European Union for a legalization measure to be introduced. The Minister previously indicated that the European Union’s approval would be required prior to a formal introduction of a legalization measure in Germany. Every day that the European Union lobbying process drags on pro-cannabis lawmakers in Germany grow increasingly frustrated, and rightfully so.

At some point in 2023 a German legalization measure needs to be introduced, regardless of if it has the blessing of the European Union or not. If the European Union does grant its approval in the coming months, that would nearly guarantee legalization’s passage in Germany not too long after the granting of the approval. However, in a scenario in which the European Union does not grant its approval in the first half of 2023, the pressure to introduce a measure in the second half of 2023 will be enormous. After all, legalization was part of the German governing coalition’s agreement once the 2021 election results were finalized.

It’s likely a safe bet that Germany’s Health Minister will not receive the same level of grace in 2023 that he did last year, and as we have already seen, there will be budgetary ramifications for any perceived delays. If pressure proves to be enough to get a measure introduced early enough in 2023, and the measure is truly in line with the spirit of the coalition government’s previously agreed upon legalization goals, then legalization could certainly occur in Germany in 2023. If that happens, that will, in turn, boost legalization’s chances on the other side of the Atlantic Ocean.

Clinical Trial Finds CBD More Effective Than Conventional Treatments At Treating Skin Ulcers

Written by Frank Schuler on January 8, 2023. Posted in Science.

According to the American Cancer Society, skin cancer is the most common form of cancer. In fact, more than 1.5 million people were diagnosed with some form of skin cancer in the year 2020 alone.

It’s a serious health condition that is expected to only increase in prevalence going forward, with cases of skin cancer expected to increase as much as 50% around the world between now and 2040. Depending on the type of skin cancer a person has, and how severe it is, many cases of skin cancer are treatable.

Other skin conditions may be rarer compared to skin cancer and do not receive as much attention, however, they can still be very serious. One such skin condition is scleroderma, which involves inflammation of the skin. Some patients develop skin ulcers as a result of scleroderma.

Researchers in Italy recently examined CBD topical’s ability to treat skin ulcers, and they found that CBD topicals were more effective compared to conventional treatments. Below is more information about it via a NORML news release:

Modena, Italy: The administration of a topical extract preparation of CBD effectively mitigates wound-related pain and promotes the healing of skin ulcers in patients with scleroderma, according to randomized trial data published in the journal Advances in Skin & Wound Care. Scleroderma (a/k/a systemic sclerosis) is a rare autoimmune disorder involving the tightening of the skin and the narrowing of blood vessels.

Italian investigators assessed the efficacy of topical CBD oil compared to conventional medications in a group of scleroderma patients with digital ulcers (skin ulcers of the fingertips). Twenty-five patients were randomly selected to use CBD for one month; the other 20 received conventional therapy.

Subjects in the CBD group experienced greater pain relief and wound healing than did those in the control group. Authors reported, “Although mean wound-related pain NRS [numeric rating scale] scores did not differ between CBD-treated patients and control patients at baseline, their mean scores differed significantly after 1 month.” Specifically, patients in the treatment group experienced a decrease in pain of 29 percent over the course of the trial, whereas those in the control group only experienced a six percent decrease.

Investigators further acknowledged, “In terms of DU [digital ulcer] healing, 18 of the 25 patients in the CBD-treated group (72 percent) experienced complete healing by the end of the study. In contrast, complete healing was observed in (only) 6 of the 20 control group participants (30 percent).”

Patients receiving CBD treatment reported “no significant adverse effects” during the study.

“The present study is the first to report the effectiveness of local CBD treatment in the management of SSc-DUs [systemic sclerosis digital ulcers],” authors concluded. “Topical administration of CBD is a safe, effective, noninvasive tool that is associated with improved wound-related pain, DU healing, and QoL [quality of life] of patients with SSc.”

The topical application of cannabinoids, and of CBD in particular, has demonstrated benefits in the treatment of a variety of skin-related conditions, including psoriasis, erythema, pruritis, and acne. It has also been associated with wound healing in patients with refractory leg ulcers and with the rare skin blistering disease epidermolysis bullosa.

Full text of the study, “Topical cannabidiol in the treatment of digital ulcers in patients with scleroderma: Comparative analysis and literature review,” appears in Advances in Skin & Wound Care.

Joints cannabis flower Joints cannabis flower Joints cannabis flower Joints cannabis flower Joints cannabis flower

UK Study Finds That Cannabis Is Associated With Improvements In Depressive Symptoms

Written by Frank Schuler on January 8, 2023. Posted in Science.

Depression is a common mental health condition affecting people all over the globe. Major depressive disorder, or depression as it is more often referred to, negatively affects how people feel, think, and act.

The condition can be caused by any number of things, or combination of things, including deficient mood regulation by the patient’s brain, genetic susceptibility, grief, and/or stressful events that have occurred in the person’s life.

Common symptoms include sadness, loss of interest in things the patient previously enjoyed, changes in appetite, insomnia, loss of energy, difficulty focusing, and/or thoughts of death or suicide.

Fortunately, depression can be treated, with the cannabis plant being increasingly used by patients to help battle depression. A team of researchers in the United Kingdom recently examined cannabis use by patients suffering from depression and the results are encouraging. Below is more information about it via a NORML news release:

London, United Kingdom: The daily consumption of cannabis products is associated with sustained improvements in depressive symptoms, according to observational trial data published in the journal Expert Review of Neurotherapeutics.

British investigators assessed the safety and efficacy of cannabis products in 129 subjects with a primary diagnosis of depression. Study subjects were participants in the UK Medical Cannabis Registry and all possessed a doctor’s authorization to consume cannabis. Study participants consumed either cannabis extracts, THC-dominant flowers, or both for a period of six-months.

Researchers reported: “The results showed that medicinal cannabis was associated with improvements in depression and anxiety symptoms, as well as health-related quality of life, and sleep quality after 1, 3, and 6 months of treatment.” While some subjects reported adverse events from cannabis products, almost all side effects were classified as either “mild or moderate.”

Authors concluded, “Future studies could focus on conducting controlled observational studies or pilot trials to determine the potential of CBMPs [cannabis-based medicinal products] as a treatment for depression.”

Post-traumatic stress patients enrolled in the UK Medical Cannabis Registry have similarly shown sustained symptomatic improvements following cannabis therapy.

Full text of the study, “Assessment of clinical outcomes of medicinal cannabis therapy for depression: Analysis from the UK Medical Cannabis Registry,” appears in the Expert Review of Neurotherapeutics.

Cannabis Compounds Effective At Mitigating Chronic Pain And Improving Sleep According To New Study

Written by Frank Schuler on January 8, 2023. Posted in Science.

Neuropathic pain is a major health condition affecting a significant percentage of the global population. Neuropathic pain involves a patient’s nervous system being damaged or not working correctly due to various reasons.

Common causes of neuropathic pain include, but are not limited to, nerve pressure or nerve damage after surgery or trauma, infections, cancer, extreme alcohol use, and conditions such as multiple sclerosis and diabetes.

A common condition that accompanies chronic neuropathic pain is an inability to gain proper sleep. Neuropathic pain patients often report difficulty falling asleep and/or staying asleep, largely due to the pain that they are experiencing.

A team of researchers in Canada recently examined randomized controlled trial data involving neuropathic pain, sleep, and medical cannabis use and the results of their research was very insightful. Below is more information about it via a news release from NORML:

Toronto, Canada: Cannabis compounds are effective at mitigating chronic neuropathic pain and improving sleep, according to a review of randomized controlled trial data published in the journal Regional Anesthesia & Pain Medicine.

A team of Canadian researchers evaluated results from nine trials that compared synthetic and natural cannabinoids to placebo in patients suffering from neuropathic pain syndromes.

They reported: “Meta-analysis of data from six studies showed that cannabinoids were associated with a significant improvement in sleep quality. Meta-analysis of data from eight studies showed a significant reduction in daily pain scores in the cannabinoid group.”

Authors concluded: “Cannabinoids have a role in treating chronic neuropathic pain as evidenced by significant improvements in sleep quality, pain intensity, and PGIC [Patients’ Global Impression of Change scale]. More research is needed to comprehensively evaluate the impact of cannabinoids on sleep health and analgesic efficacy.”

Survey data consistently reports that patients who use cannabis products typically do so to mitigate chronic pain and improve sleep. Among patients in US states where medical cannabis access is permitted, over 60 percent are qualified to use it to treat pain.

Full text of the study, “Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: A systematic review and meta-analysis of randomized controlled trials,” appears in Regional Anesthesia & Pain Medicine. Additional information on cannabis and chronic pain is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.

Medical Cannabis Products Now Covered By Government-Funded Health Insurance In Colombia

Written by Hazel Norman on January 8, 2023. Posted in Policy.

In 2022 Colombia’s Health Ministry approved the expansion of health insurance coverage of certain medical procedures and medications, including expansion to cover some medical cannabis products. The effective date for the expanded coverage was January 1, 2023.

While it never seemed to be in doubt that the medical cannabis insurance coverage would ultimately take effect, it was reassuring to see that the new coverage was indeed implemented, with reassurances provided by the Health Ministry.

News of the reassurances came via a press release from Khiron Life Sciences Corp late this week. Below are excerpts from the press release:

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces that the new Colombian Government has included plant-based medical cannabis products (i.e., Khiron products) in the list of mandatory insurance-covered medications starting January 1^st, 2023, as well as the signing of a first-of-its-kind medical cannabis contract with one of Colombia´s largest insurance companies based in the city of Bogota.

Resolution 2808 of 2022 was signed by the Ministry of Health on December 30, 2022. This revision was necessary to remove unintended ambiguities that had arisen whether plant-based magistral preparations from medical cannabis (i.e., Khiron products) were also included in the insurance coverage. This is now once and for all clearly confirmed. The new government is fully committed with the use of medical cannabis as a covered treatment under the Colombian health system.

The Government used this iteration to also validate medical conditions where they find moderate to strong evidence that cannabis is an effective treatment. These medical conditions evaluated by the IETS (Technical Institute of the health Sector) include chronic and neuropathic pain, oncology pain, sleep disorders, epilepsy, and fibromyalgia, which represent the primary conditions treated with Khiron products.

During the first half of 2022, insurance-covered prescriptions represented more than 90% of the Company´s cannabis sales in Colombia. With a patient base of more than 25,000 patients, Khiron will immediately resume filling insurance-covered prescriptions through its Zerenia clinic network.

Alvaro Torres, CEO of Khiron, comments: “Today is a great day for patients in Colombia and Khiron. We welcome the decision from the new Colombian government to categorically mandate insurance coverage for our medical cannabis products. With this decision, Khiron will immediately tackle the backlog of covered medical cannabis products to our patients. In parallel, we have also secured a first-of-its-kind contractual relationship with one of Colombia´s largest government-owned insurance companies for medical cannabis specific healthcare services and dispensation. These two achievements, will allow us to revert to predictable recurring revenues, shorter collection periods and improved cashflow.”